Canopy Biosciences

Now part of Bruker Spatial Biology, Canopy Biosciences was a biotechnology company that specialized in providing access to multiomics technologies for spatial biology and gene expression profiling. Established in St. Louis, Missouri, Canopy Biosciences developed a spatial proteomics instrument and also offered a range of services to support oncology and immunology research. Services included spatial transcriptomics, gene expression, spatial proteomics, and data analysis.
History
2016 (foundation)
Canopy Biosciences was founded in 2016 with the goal of commercializing academic technologies and offering access (as a service provider) to multiomics tools for gene expression analysis. The company was established by BioGenerator, an investment arm of BioSTL, which provides startup capital and support to bioscience companies.
2019 (strategic acquisitions)
In 2019, Canopy Biosciences raised a Series B round led by Ampersand Capital Partners, which was used to acquire Zellkraftwerk GmbH and CORE Diagnostics. The acquisition of Zellkraftwerk GmbH brought ChipCytometry technology and the ZellScannerONE instrument to Canopy, enhancing its spatial immunophenotyping capabilities. CORE Diagnostics, a provider of CLIA-certified laboratory services, expanded Canopy’s offerings to include clinical diagnostics, histology, IHC, and FISH (fluorescence in situ hybridization).
2020 (acquisition by Bruker)
In 2020, Canopy Biosciences was acquired by Bruker Corporation, a manufacturer of scientific instruments. This acquisition allowed Canopy to leverage Bruker's global infrastructure and expertise in product design and engineering. The financial terms of the deal were not disclosed.
2022-2024 (recent developments)
In 2022, Canopy Biosciences launched the CellScape Precise Spatial Multiplexing platform, integrating fluidics for automation and offering high-resolution imaging for multiplex immunofluorescence. In 2023, Canopy partnered with Enable Medicine to integrate advanced spatial analysis tools into the CellScape platform.
In 2024, Bruker Corporation acquired the assets from NanoString Technologies, expanding its spatial biology capabilities. The assets from the NanoString acquisition were merged with Canopy Biosciences and another Bruker-owned subsidiary, Bruker Spatial Genomics, to form a new division, Bruker Spatial Biology.
Technologies
* ZellScannerONE: Part of the Zellkraftwerk acquisition, the ZellScannerONE instrument enables the detection of up to 100 biomarkers in a single assay using ChipCytometry technology. The ZellScannerONE was discontinued in 2025.
* CellScape Precise Spatial Proteomics: The CellScape instrument utilizes cyclic multiplex immunofluorescence (mIF) for spatial proteomics, offering single-cell resolution whole-slide imaging. The platform features to detect both high- and low-expressing biomarkers. Launched originally as "CellScape Precise Spatial Multiplexing: The Next-Generation ChipCytometry Instrument", the CellScape platform improved upon the ZellScannerONE instrument by adding fluidics integration and sharper optical capabilities.
* VistaPlex Multiplex Assay Kits: These pre-validated antibody panels are compatible with the CellScape platform, enabling modular assay design with fast time to results.
Services
* Spatial Biology: The company offers spatial transcriptomics and spatial proteomics services to support researchers doing both discovery and translational work.
* Gene Expression: Canopy Biosciences offers services for bulk gene expression analysis.
* Histology, Immunohistochemistry (IHC), and Multiplex Fluorescence in situ Hybridization (FISH): The company provides histology and IHC services for protein expression analysis and for detecting multiple RNA molecules within tissue samples.

Main Menu

See Also

Main Menu